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Sorely missing from the ‘‘toolkit’’ for directed differ-
entiation of stem/progenitor cells are agonists of the
BMP-signaling pathway. Using a high-throughput
chemical screen, we discovered that PD407824, a
checkpoint kinase 1 (CHK1) inhibitor, increases the
sensitivity of cells to sub-threshold amounts of
BMP4. We show utility of the compound in the
directed differentiation of human embryonic stem
cells toward mesoderm or cytotrophoblast stem
cells. Blocking CHK1 activity using pharmacological
compounds or CHK1 knockout using single guide
RNA (sgRNA) confirmed that CHK1 inhibition in-
creases the sensitivity to BMP4 treatment. Additional
mechanistic studies indicate that CHK1 inhibition de-
pletes p21 levels, thereby activating CDK8/9, which
then phosphorylates the SMAD2/3 linker region,
leading to decreased levels of SMAD2/3 protein and
enhanced levels of nuclear SMAD1. This study pro-
vides insight into mechanisms controlling the BMP/
transforming growth factor beta (TGF-b) signaling
pathways and a useful pharmacological reagent for
directed differentiation of stem cells.
INTRODUCTION
Bone morphogenetic proteins (BMPs) are important regulators
of embryonic development and stem/progenitor cell fate deci-
sions. BMPs are required for the establishment of the body
plan (Heisenberg and Solnica-Krezel, 2008), limb bud patterning
(Robert, 2007), and early hemato-vascular (Larsson and Karls-
son, 2005) and neural development (Liu and Niswander, 2005).
BMPs regulate the development of multiple organs, including
heart (Kruithof et al., 2012), kidney (Cain et al., 2008), liver (Zaret,
2001), and the CNS (Fukuda and Taga, 2006). In adult tissues,
BMPs provide signals for differentiation in niches for the hair fol-
licle (Blanpain and Fuchs, 2009), intestinal stem cells (Takashima
andHartenstein, 2012), and germ cells (Knight andGlister, 2006).
Due to their important role in embryonic development, BMPs
have been used in both maintenance and directed differentiationCell
This is an open access article under the CC BY-Nof embryonic stem cells (ESCs) to various cell fates. For mouse
ESCs, BMP4 is required, together with leukocyte inhibitory fac-
tor, to maintain the pluripotent self-renewal state (Li et al.,
2012; Ying et al., 2003). In contrast, in human ESCs, BMP4 pro-
motes differentiation, so that inhibition of BMP signaling is
required to maintain human ESC self-renewal (James et al.,
2005; Wang et al., 2005). Once committed to differentiate,
BMPs promote the commitment of ESCs to the mesendoderm
germ layer, and these BMP-induced mesendoderm cells can
further differentiate into multiple cell lineages, including cardiac,
hematopoietic, and hepatic cells. For example, BMP4 has been
used to direct differentiation from mesendoderm to Flk1+ he-
matopoietic progenitor cells and then to blood cells (Lengerke
et al., 2008; Nostro et al., 2008). BMP2 and BMP4 direct defini-
tive endoderm cells to a hepatic lineage (Gouon-Evans et al.,
2006). BMP7 has been used for differentiation toward brown ad-
ipocytes (Nishio et al., 2012). In addition, BMP4 initiates tropho-
blast differentiation from human ESCs (Xu et al., 2002). Finally,
BMP4, 7, and 8b induce germ cell differentiation from both
mouse and human ESCs (Kee et al., 2006; Wei et al., 2008).
Synthetic small molecules have been widely used to control
developmental signaling pathways, as functional agonists or an-
tagonists. Compared to recombinant proteins, synthetic small
molecules can bemore stable, easier to quantify for reproducible
activity and dose response, and far less expensive to produce,
which is particularly relevant for scaling cell production. To
date, most of the small molecules discovered to regulate BMP
signaling are BMP antagonists. A phenotypic screen using ze-
brafish embryos identified dorsomorphin, which inhibits BMP
signaling by targeting BMP type 1 receptors (ALK2, 3, and 6)
(Yu et al., 2008). A structure-activity relationship study found a
dorsomorphin analog, LDN193189, which demonstrates moder-
ate pharmacokinetic characteristics in mice (Cuny et al., 2008).
The in vivo structure-activity relationship study of dorsomorphin
analogs identified a specific BMP inhibitor, DMH1 (Hao et al.,
2010). Recently, several small molecules have been identified
to either activate or synergize with the BMP pathway. For
example, SVAK-3 (Okada et al., 2009), SVAK-12 (Kato et al.,
2011), KM11073 (Baek et al., 2015), and A1 and A17 (Cao
et al., 2014) enhance BMP2-induced early osteoblast marker
expression. Small molecules of the flavonoid family have been
shown to upregulate Id1, Id2 expression in a human cervical car-
cinoma cell line (Vrijens et al., 2013). In addition, FK506 activatesReports 15, 2063–2075, May 31, 2016 ª 2016 The Author(s). 2063
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1. PD407824 Sensitizes C2C12 Myoblasts to BMP4-Induced Activation of BMP Signaling
(A) Scheme of the high-throughput screening.
(B) Chemical structure of PD407824.
(C) Dose curve of PD407824 on C2C12 myoblasts transfected with pId2-Luc-GFP reporter.
(D) PD407824 sensitizes C2C12 myoblasts to BMP4-induced upregulation of endogenous Id2 expression measured by qRT-PCR.
(E) PD407824 sensitizes C2C12 myoblasts to BMP4-induced SMAD1/5/9 phosphorylation indicated by western blotting.
(F) Quantification of relative SMAD1/5/9 activity. The phosphorylation levels were normalized to total SMAD1 protein.
(G) PD407824 sensitizes C2C12 myoblasts to BMP4-induced upregulation of Id1 expression measured by qRT-PCR.
See also Figure S1.BMPR2 and rescues endothelial dysfunction (Spiekerkoetter
et al., 2013). However, most of the identified compounds show
relatively low activity and fail to induce the generation of mature
osteoblasts, which limits their application to modulate BMP
signaling. Thus, there is still a strong need to identify efficient
BMP activators or sensitizers that can be used in stem cell
differentiation.
From a high-throughput screen of more than 4000 small mol-
ecules we identified PD407824 as a chemical BMP sensitizer.
PD407824 sensitizes cells to BMP4-induced upregulation of
BMP pathway target genes, including Id1 and Id2. More impor-
tantly, we found that PD407824 cooperates with limiting BMP4
protein when added to ESCs during differentiation towardmeso-
derm or cytotrophoblast stem cells. This provides a useful chem-
ical agent to control human ESC (hESC) differentiation and can
facilitate scaled production of defined cell lineages from hESCs.
RESULTS
Identification of PD407824 as a BMP4 Sensitizer
To identify chemical agonists/sensitizers of BMP signaling, we
established an assay to monitor BMP-signaling activity through2064 Cell Reports 15, 2063–2075, May 31, 2016the expression of a downstream target, Id2 (Figure 1A). We
designed a reporter construct containing the Id2 promoter,
including two previously validated BMP-responsive regulatory
regions from 3,000 to 2,729 and 350 to +80 (Nakahiro
et al., 2010) controlling expression of a luciferase-GFP reporter
(pId2-LucGFP). The reporter activity was first validated as
responsive to BMP4. C2C12 myoblasts transfected with the
pId2-LucGFP reporter construct showed increased luciferase
activity when treated with 10 ng/ml BMP4 (Figure S1A). To
perform high-throughput screening, C2C12 myoblasts were first
seeded onto 10-cm2 plates in standard medium (DMEM supple-
mented with 10% fetal bovine serum [FBS]). On the second day,
these cells were transfected with the reporter plasmid pId2-
LucGFP. 24 hr later, the transfected cells were transferred to
384-well plates at 5,000 cells/100 ml medium per well. After over-
night incubation, the culturemediumwas changed to serum-free
(DMEM lacking FBS) to decrease the background luciferase
activity induced by serum. After 24 hr, each well was treated
with a single compound from a library containing 4,000 chemi-
cals, including kinase inhibitors, signaling pathway regulators,
natural products, and US Food and Drug Administration (FDA)-
approved drugs, which were arrayed similarly in 384-well
format as 10 mM stocks in DMSO. Detailed library information
is described in Table S1. The library was screened at 1:1,000
(0.1% DMSO) and 1:10,000 (0.01% DMSO) dilutions, providing
10 mM and 1 mM final concentrations, respectively. After
24-hr chemical treatment, the cells were lysed and analyzed
for luciferase activity using the Bright-Glo luciferase substrate
(Promega).
The effect of compound on luciferase activity was quantified
by calculating the fold-induction compared to samples treated
with DMSO alone, which served as negative controls. BMP4 at
10 ng/ml was used as a positive control. The compounds
showing more than 5-fold induction were chosen as the primary
hits for further analysis (Figure S1B; Table S2). Although the cells
were cultured in serum-free medium for 24 hr in the primary
assay, there might remain some baseline level of BMP signaling
(as demonstrated below). In this case, we might expect to iden-
tify both BMP agonists and BMP sensitizers in the primary
screen. The primary hit compounds were titered and three of
them showed reporter induction at a relatively low effective con-
centration (1–15 mM). One hit compound, isoliquiritigenin, has
been previously reported to upregulate alkaline phosphatase
(ALK) expression (Vrijens et al., 2013). Since ALK is an early
marker of osteoblast differentiation, we further tested the three
hit compounds for their capacity to induce bone formation. We
could detect ALK expression. However, the hit compounds
were unable on their own to induce the generation of mature os-
teoblasts. C2C12 myoblasts were treated with hit compounds
for 21 days and stained with alizarin red S to examine the miner-
alization of mature osteoblasts. We did not find cells staining
positive by alizarin red S in compound-treated conditions
(Figure S1C).
Since hit compounds themselves did not significantly induce
a functional BMP cellular output, we tested whether hit com-
pounds make the cells more sensitive to BMP4 treatment,
considering that the primary screen might not be entirely
depleted of BMP signals. Using the same platform as for
primary screening (Figure 1A), after overnight starvation,
C2C12 myoblasts expressing pId2-LucGFP were treated with
hit compounds together with 1 ng/ml BMP4. One hit compound,
PD407824 (Figure 1B), sensitized C2C12 myoblasts to 1 ng/ml
BMP4 or 0.1 ng/ml BMP4 treatment to increase luciferase activ-
ity (Figure 1C). Two criteria were used to define the sensitizing ef-
fect. First, activity of the reporter in cells treated with PD407824
and BMP4 simultaneously is higher than the sum of the activities
in cells treated with PD407824 or BMP4 separately. More
importantly, the half maximal effective concentration (EC50) of
PD407824 decreases as the BMP4 concentration increases
(EC50 = 12.3 mM in the absence of BMP4; EC50 = 0.75 mM in
the presence of 0.1 ng/ml BMP4; EC50 = 0.12 mM in the presence
of 1 ng/ml BMP4). Neither of the two other primary screen hits,
isoliquiritigenin or lindane, showed the same synergistic effect
with BMP4. To determine whether PD407824 + BMP4 activates
endogenous Id2 expression, C2C12 myoblasts were treated
with 10 mM or 1 mM PD407824 plus different doses of BMP4
for 24 hr and analyzed for Id2 expression with quantitative
RT-PCR. Consistent with the pId2-LucGFP assay, PD407824
sensitizes C2C12myoblasts to BMP4 treatment to increase tran-
scription of the endogenous Id2 gene. DMSO + 10 ng/ml BMP4increased Id2 transcript levels 3.7 ± 1.0-fold; while 1 or 10 mM
PD407824 + 10 ng/ml BMP4 treatment increased the Id2 tran-
script levels 9.6 ± 2.2-fold, and 11.5 ± 0.7-fold, respectively (Fig-
ure 1D). Together, these data suggest that PD407824 can sensi-
tize C2C12 myoblasts to sub-threshold concentrations of BMP4
treatment to upregulate expression of Id2, a known target of the
BMP-signaling pathway.
To examine whether PD407824 does in fact affect BMP-
signaling components, we used western blotting experiments
to measure the phosphorylation of SMAD1/5/9 at Ser 463/
465 (Figure 1E). As shown by the DMSO control, we confirmed
a low basal level of activated SMAD1/5/9. However,
PD407824+BMP4 quantitatively increased SMAD1/5/9 phos-
phorylation. Interestingly, PD407824 used alone at the same
concentration showed a trend to slightly decrease phosphory-
lated SMAD1/5/9, which was however not statistically significant
(Figure 1F). In addition, qRT-PCR was used to measure the
expression of Id1, another known key target gene of BMP
signaling. PD407824 sensitizes C2C12 myoblasts to sub-
threshold concentrations BMP4 treatment to upregulate Id1
transcript levels in a dose-dependent manner (Figure 1G).
Together, these data suggest that PD407824 sensitizes C2C12
myoblasts to sub-threshold concentrations of BMP4 to activate
BMP signaling.
PD407824 Synergizes with BMP4 to Reprogram C2C12
Myoblasts toward a Mature Osteoblast Fate
BMPs are key drivers of bone formation, and previous studies
indicated that BMP treatment can reprogram C2C12 myoblasts
to osteoblasts (Katagiri et al., 1994). To determine the impact of
PD407824 inmediating BMP-dependent bone formation, C2C12
myoblasts were treated with DMSO as a control, PD407824,
3 ng/ml BMP4, PD407824 + 3 ng/ml BMP4, or 10 ng/ml BMP4.
After 6 days of culture, cells were fixed and stained with ALK
substrate. In the DMSO control, C2C12 myoblasts spontane-
ously differentiated into myotubes, but there were no ALK-ex-
pressing cells (whichwould display a purple color from the stain).
There were a very limited number of ALK-expressing cells de-
tected in the sample treated with 3 ng/ml BMP4, suggesting
this is near or below a bone forming threshold. Indeed, the sam-
ple containing 10 ng/ml BMP4 (with DMSO but no compound
added) showed a strong induction of ALK expression, although
there remained numerous myotubes, suggesting that DMSO +
10 ng/ml BMP4 is not sufficient to block myogenesis.
PD407824 treatment alone was not sufficient to block myogen-
esis or induce ALK expression. However, cells treated with
PD407824 + 3 ng/ml BMP4 expressed high levels of ALK and
entirely lost the capacity to form myotubes (Figure 2A).
Next, C2C12 myoblasts were treated with different doses
of PD407824 in the presence or absence of 3 ng/ml BMP4. Six
days later, the cell lysates were analyzed for ALK activity using
an absorbance-based ALK substrate. The quantitative results
confirmed that PD407824 itself does not induce ALK activity;
however, PD407824 synergized with 3 ng/ml BMP4 to repro-
gram C2C12 myoblasts to ALK-expressing cells in a dose-
dependent manner. The ALK activity generated by cells treated
with 1 mM PD407824 + 3 ng/ml BMP4 was equal to that of cells
treated with 10 ng/ml BMP4 alone (Figure 2B).Cell Reports 15, 2063–2075, May 31, 2016 2065
A B
C D
Figure 2. PD407824 Synergizes with BMP4 to Reprogram C2C12 Myoblasts into Mature Osteoblasts
(A) C2C12 myoblasts were reprogrammed into cells expressing osteogenic marker alkaline phosphatase (ALK).
(B) Quantification of ALK activity by fluorescence-based substrate.
(C) qRT-PCR to detect the expression of mature osteoblast markers, including collagen I (collagen), osteopontin (OPN), and osteocalcin (OC).
(D) Alizarin red S staining of the mature osteoblasts. PD: PD407824.
Scale bar, 50 mm.In addition to ALK, we also examined by qRT-PCR the expres-
sion of other osteoblast markers, including collagen I, osteopon-
tin and osteocalcium. Consistent with the ALK substrate assay,
PD407824 or 3 ng/ml BMP4 itself was not sufficient to induce
bone formation. In contrast, PD407824 + 3 ng/ml BMP4 treat-
ment was able to effectively induce the expression of osteoblast
markers. The expression levels of these markers in cells treated
with 1 mM PD407824 + 3 ng/ml BMP4 was comparable to those
in the cells treated with 10 ng/ml BMP4 (Figure 2C). We also
examined the presence of mineralization to evaluate the
formation of mature osteoblasts. C2C12 myoblasts were treated
with DMSO as control, PD407824 alone, 3 ng/ml BMP4,
PD407824 + 3 ng/ml BMP4, or 10 ng/ml BMP4 for 22 days and
then stained with alizarin red S solution. In the cells treated
with DMSO, 3 ng/ml BMP4, or 1 mMPD407824, no alizarin stain-
ing was detected. The cells treated with PD407824 + 3 ng/ml
BMP4 showed strong mineralization, comparable to the cells
treated with 10 ng/ml BMP4 (Figure 2D). Altogether, these data
suggest that PD407824 synergizes with BMP4 to reprogram
C2C12 myoblasts into mature osteoblasts.
PD407824 as a BMP Sensitizer to Induce hESC
Differentiation to Mesoderm
BMP4 has been widely used to induce hESC differentiation. The
effect of BMP4 in hESC differentiation is context dependent.
When cells are allowed to differentiate as embryoid bodies
(EBs), the addition of BMP4directsmouse and humanESCdiffer-2066 Cell Reports 15, 2063–2075, May 31, 2016entiation to mesoderm, which subsequently generates beating
cardiomyocytes (Cao et al., 2013; Kattman et al., 2011; Yang
et al., 2008). In order to determine whether PD407824 increases
hESCsensitivity toBMP treatment in amesodermal differentiation
protocol, hESCH9cellswere treatedwithDMSOor threedifferent
concentrations (0.1 mM, 0.3 mM, and 1 mM) of PD407824 com-
bined with 3 ng/ml BMP4 for 4 days and analyzed with qRT-
PCR. Consistent with the effect on C2C12 cells, PD407824 sensi-
tizes H9 cells to BMP4 treatment to increase transcription of the
endogenous Id2gene. 1mMPD407824+3ng/mlBMP4 treatment
increased the Id2 transcript levels 7.1 ± 0.3-fold higher than
DMSO + 3 ng/ml BMP4 (Figure 3A). Strikingly, PD407824 +
3 ng/ml BMP4 treatment increases transcript levels of Brachyury
T, a mesoderm marker, similar as when treated with 10 ng/ml
BMP4, suggesting PD407824 sensitizes hESCs to BMP4 treat-
ment during mesoderm differentiation. To further validate that
PD407824 + BMP4 induces the generation of functional meso-
derm, the chemically treated cells were examined for their capac-
ities to form beating cardiomyocytes, which aremesoderm deriv-
atives. After 4 days treatment with PD407824 + BMP4, EBs were
subsequently cultured in cardiac differentiation medium initially
containing 20% FBS, which after 10 days was reduced to 2.5%.
We used DMSO + 10 ng/ml BMP4 as a positive control, and after
10 days counted the number of beating colonies. In wells treated
with 1 mM PD407824 + 3 ng/ml BMP4 the number of beating
colonies was comparable to wells treated with 10 ng/ml BMP4
(Figure 3B); notably, treatment with 3 ng/ml BMP4 alone was
A B C
D
E
Figure 3. PD407824 Sensitizes Cells to BMP4 Treatment during hESC Mesodermal Differentiation
(A) qRT-PCR analysis of ID2 and Brachyury T expression. EBs were treated with either DMSO or three different concentrations (0.1, 0.3, or 1 mM) of PD407824
combined with two concentrations (3 or 10 ng/ml) of BMP4 for 4 days and analyzed with qRT-PCR. DMSO + 3 ng/ml BMP4 was used as a control to normalize
data. DMSO + 10 ng/ml BMP4 was used as a positive control.
(B) Quantification of beating colonies on day 10.
(C) qRT-PCR analysis of the expression levels of human cardiomyocyte markers TNNT2,MHY6, andMLC2v. Levels were normalized to DMSO + 3 ng/ml BMP4.
RNA was isolated on day 12 for qRT-PCR analysis.
(D) Immunofluorescence staining for TNNT2 expression. Scale bar, 100 mm. Cells were fixed on day 12 and stained for the cardiomyocyte marker TNNT2.
(E) Intracellular flow cytometry and quantification of the percentage of TNNT2+ cells.not sufficient to generate beating colonies. Importantly, the cells
treated with 1 mM PD407824 + 3 ng/ml BMP4 expressed high
levels of cardiomyocyte differentiationmakers, including troponin
T type 2 (TNNT2), myosin heavy chain 6 (MHY6), andmyosin light
chain 2v (MLC2v), at day 12 of differentiation, shown by qRT-PCR
(Figure 3C). The expression levels of these genes in the cells
treated with 1 mM PD407824 + 3 ng/ml BMP4 treatment were
comparable to cells treated with 10 ng/ml BMP4. Moreover, we
used immunocytochemistry to examine TNNT2 protein expres-
sion. Multiple concentrations (0.1, 0.3, and 1 mM) of PD407824 +
3ng/mlBMP4efficientlyenhancedTNNT2expression (Figure3D).
Intracellular flow cytometry was used to quantify the differentia-
tion efficiency. The percentage of TNNT2+ cells in the samples
treated with 1 mM PD407824 + 3 ng/ml BMP4 (42.6% ± 4.3%)
was significantly enhanced compared to 3 ng/ml BMP4 alone
(5.5% ± 0.7%), achieving the level found in cells treated with
10 ng/ml BMP4 (47.5%± 6.7%) (Figure 3E). Thus, PD407824 sen-
sitizes cells to sub-threshold concentrations of BMP4 during
hESC mesodermal differentiation.PD407824 Sensitizes hESCs to BMP4 during
Differentiation toward Cytotrophoblast Stem Cell
Lineage
The effect of BMP4 on hESC differentiation is stage and context
dependent. We next sought to determine if the action of
PD407824 is specific to BMP-dependent mesodermal differenti-
ation or can bemore generally applied to BMP-dependent differ-
entiation programs. When hESCs are grown in the presence
of mouse embryonic fibroblast (MEF) conditional medium
(CM), BMP4 functions as a key driver for differentiation toward
KERATIN7 (KRT7)+/TP63+ cytotrophoblast stem cells (Amita
et al., 2013; Das et al., 2007; Li et al., 2013; Xu et al., 2002). To
determine if PD407824 functions as a BMP sensitizer in tropho-
blast differentiation, hESC H1 cells were treated with DMSO or
2.5 mM PD407824 combined with different concentrations of re-
combinant BMP4 protein (0, 4, 6, 9, 12, or 30 ng/ml) in MEF-CM
for 7 days (Figure 4A). The cells were fixed and stained with anti-
KRT7 antibody (Figure 4B). More KRT7+ cells were detected in
PD407824 + BMP4 treatment condition than the correspondingCell Reports 15, 2063–2075, May 31, 2016 2067
AB
C D
E
Figure 4. PD407824 Sensitizes Cells to BMP4 Treatment during Differentiation of hESCs toward Cytotrophoblast Stem Cell Fate
(A) Scheme of human cytotrophoblast stem cell differentiation. hESC H1 cells were treated with DMSO or 2.5 mM PD407824 combined with different concen-
trations of recombinant BMP4 protein (0, 4, 6, 9, 12, or 30 ng/ml) in MEF-CM for 7 days.
(B) Immunohistochemistry analysis of KRT7 expression. Scale bar, 100 mm.
(C and D) Intracellular flow cytometry analysis (C) and quantification (D) of the percentage of KRT7+ cells.
(E) qRT-PCR analysis of the expression of human cytotrophoblast stem cell markers KRT7, TP63, andGCM1. Levels were normalized to undifferentiated hESCs.
See also Figure S2.
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Figure 5. PD407824 Functions through
Inhibiting CHK1
(A and B) CHIR124, a CHK1 inhibitor, mimics the
effect of PD407824 to sensitize BMP4-induced
upregulation of Id2 expression (A) and increased
SMAD1/5/9 phosphorylation (B) in C2C12
myoblasts. The relative Id2 transcript level was
normalized to DMSO treatment conditions. The
relative SMAD1/5/9 phosphorylation was normal-
ized to total SMAD1.
(C) Relative Id2 transcript expression in CHK1+/
and CHK1/ cells. Untransfected cells (wild-type
[wt]) and cells infected with sgRNA targeting GFP
were used as controls.
See also Figure S3.BMP4 treatment condition. Intracellular flow cytometry was used
to quantify the differentiation efficiency (Figure 4C). PD407824
treatment significantly increased the percentage of KRT7+ cells
in different doses of BMP4 treatment. (Figure 4D). Moreover,
qRT-PCR analysis showed that cells treated with 2.5 mM
PD407824 + 9 ng/ml BMP4 express other cytotrophoblast
stem cells markers, such as TP63 (Li et al., 2013) andGCM1 (Fig-
ure 4E). The expression levels of these genes when treated with
2.5 mM PD407824 + 9 ng/ml BMP4 are significantly higher than
the condition treated with 9 ng/ml BMP4 and were comparable
to the condition treated with 30 ng/ml BMP4.
We further examined the proliferation and DNA damage in
PD407824 treated hESCs. First, we found that there is no signif-
icant difference in the number of Ki67+ cells detected comparing
DMSO or PD407824 treated hESCs (Figure S2A). To examine
whether CHK1 inhibition affects DNA repair, PD407824-treated
hESCs were stained using g-H2A.X antibody. Cells treated
with 10 mM etoposide were used as a staining control. No
g-H2A.X+ cells were detected in 2.5 mM PD407824 or 2.5 mM
PD407824+ 9 ng/ml BMP4-treated conditions (Figure S2B),
suggesting that PD407824 treatment does not affect DNA repair
during hESC differentiation. Together, these data show that
PD407824 increases the sensitivity of hESCs to BMP4 treatment
by more than 3-fold during differentiation toward cytotropho-
blast stem cell fate without significantly affecting cell prolifera-
tion, cell cycle, or DNA repair.
PD407824 Functions through Inhibiting Checkpoint
Kinase 1
A previous study identified PD407824 as a checkpoint kinase 1
(CHK1) inhibitor (Palmer et al., 2006). To determine whether
PD407824 functions through inhibiting CHK1, we tested another
CHK1 chemical inhibitor, CHIR124, for its ability to sensitize
C2C12 myoblasts to BMP4 treatment. C2C12 myoblasts were
treated with different concentrations of CHIR124 in the presence
or absence of 1 ng/ml BMP4. After 24 hr treatment, qRT-PCRCell Rwas used to monitor the transcript levels
of Id2. Similar to PD407824, CHIR124
synergized with BMP4 to upregulate Id2
in a dose-dependent manner (Figure 5A).
Consistently, 10 mM CHIR124 + BMP4
increases the relative phosphorylation ofSMAD1/5/9 (Figures 5B and S3A), showing the similar trend as
PD407824 + BMP4 treatment (Figure 1E). Moreover, we comple-
mented the chemical approach using a genetic strategy. C2C12
cells were infected with lentivirus expressing Cas9 and single
guide RNA (sgRNA) targeting CHK1 or, as a control, sgRNA tar-
geting GFP. Mutant cells were subcloned. Western blotting ex-
periments confirmed that the monoallelic and biallelic knockout
of CHK1 protein in CHK1+/ and CHK1/ clones, respectively
(Figure S3B). After overnight starvation, the CHK1+/ and
CHK1/ C2C12 cells were treated with 1 ng/ml or 3 ng/ml
BMP4. After 24 hr treatment, Id2 transcript levels were analyzed
with qRT-PCR. Compared to uninfected or GFP-targeted cells,
CHK1+/ and CHK1/ cells show increased expression of Id2
in the absence of added BMP4 and, similar to PD407824-treated
cells, in the presence of 1 ng/ml BMP4 (Figure 5C). In the pres-
ence of 3 ng/ml BMP4, CHK1/ cells show higher Id2 expres-
sion thanCHK1+/ cells or cells treatedwith PD407824, suggest-
ing that CHK1 might play a dose dependent effect. In addition to
CHK1, PD407824 also inhibits Wee1 and PKC (Palmer et al.,
2006). To determine whether Wee1 or PKC inhibition is involved
in the sensitizing effect of PD407824, C2C12 cells were treated
with different concentrations of MK1775, a Wee1 inhibitor (Hirai
et al., 2009), or bisindolylmaleimide II, a PKC inhibitor, neither
of which inhibit CHK1 activity, in the presence or absence of
1 ng/ml BMP4. After 24-hr treatment, qRT-PCR was used to
monitor the transcript levels of Id2. In contrast toCHK1 inhibitors,
neitherMK1775 nor bisindolylmaleimide II sensitizesC2C12 cells
to BMP4 treatment (Figures S2C and S2D). Together, these data
support a mechanism by which PD407824 impacts BMP activity
through inhibition of CHK1, but not Wee1 or PKC.
Mechanism of Action: Increasing the Sensitivity to BMP
through Depletion of SMAD2/3
In the canonical BMP pathway, the ligands exert their effects
through binding to type II serine/threonine kinase receptors
(BMPR2 for BMPs), forming an oligomeric complex. The type IIeports 15, 2063–2075, May 31, 2016 2069
receptors are consequently activated and phosphorylated
and then activate the type I receptors (ALK3 and ALK6 for
BMPs; Bandyopadhyay et al., 2013). While there are SMAD-
independent pathways (Bandyopadhyay et al., 2013), a major
mode of signal transduction occurs when activated type I recep-
tors phosphorylate intracellular receptor-regulated R-SMADs
(SMAD1/5/9 for BMPs), which associate with the co-SMAD
(SMAD4) and translocate into the nucleus. The SMAD com-
plexes interact with additional transcription factors to bind pro-
moters of target genes, such as Id2, to control their expression.
Since PD407824 + BMP4 treatment increases the Id2 expres-
sion levels in bothC2C12 cells (Figure 1D) and hESCs (Figure 3A),
we first used co-immunoprecipitation experiments to determine
whether PD407824 + BMP4 treatment leads to an increased
level of SMAD1/5/9 binding with SMAD4. Cells were treated
with 3 ng/ml BMP4 in the presence or absence of 10 mM
PD407824 for 24 hr. Proteins from the cell lysate were precipi-
tated with anti-SMAD4 antibody and subsequently probed by
blotting using anti-SMAD1 antibody. SMAD1 protein bound to
SMAD4 was most abundant in the presence of PD407824 +
BMP4 compared to other conditions (Figure 6A). Since
both SMAD2/3 (R-SMAD for transforming growth factor beta
[TGF-b]) and SMAD1/5/9 are capable of binding with SMAD4,
we used western blotting to examine the expression of
SMAD2/3 at the protein level. Strikingly, western blotting exper-
iments showed that PD407824+BMP4 treatment significantly
decreased the total protein levels of SMAD2/3 protein (Fig-
ure 6B). In addition, CHIR124, another CHK1 inhibitor, also
decreased the total levels of SMAD2/3 protein (Figure S4A).
This might due to either reduced levels of SMAD2/3 gene
expression or increased degradation of SMAD2/3 protein.
To distinguish these possibilities, C2C12 were treated with
PD407824 or PD407824 + BMP4 for 24 hr and analyzed with
qRT-PCR. Neither PD407824 nor PD407824+BMP4 treatment
significantly changed the transcript levels of SMAD2/3 (Fig-
ure S3B), suggesting that PD407824 might affect SMAD2/3 pro-
tein stability. Previous studies suggested that activated CDK8/9
phosphorylates SMAD2/3 at a linker region (pT220 for SMAD2
and pT179 for SMAD3), which is ultimately recognized by ubiq-
uitin ligase Nedd4L, leading to proteasome-mediated turnover
of SMAD2/3 (Alarco´n et al., 2009; Gao et al., 2009). Western blot-
ting experiments were used to measure the phosphorylation
of SMAD2/3 at the linker region. In conditions using PD407824
or PD407824+BMP4, the relative phosphorylation (normalized
to total SMAD2/3 protein) of linker region (T179 for SMAD3)
was significantly elevated compared to BMP4 treatment alone
(Figure 6C). The hyper-phosphorylation of the linker region leads
to the decreased levels of SMAD2/3 proteins (Figure 6B).
Since CDK9 phosphorylates the SMAD2/3 linker region, both
chemical and genetic approaches were used to determine
whether CDK9 activation is required for the sensitizing effect of
PD407824 to upregulate Id2. The cells were treated with or
without 3 ng/ml BMP4 plus PD407824 in the presence or
absence of 300 nM flavopiridol, a chemical CDK inhibitor, for
24 hr and analyzed with qRT-PCR experiments to measure
endogenous Id2 expression levels. Flavopiridol does not affect
the activity of BMP4 alone. However, flavopiridol blocks
the sensitizing effect of PD407824 with BMP4 (Figure 6D). In2070 Cell Reports 15, 2063–2075, May 31, 2016addition, flavopiridol blocks PD407824-induced elevation of
SMAD3 T179 phosphorylation, as well as the decrease of total
SMAD2/3 protein (Figures 6E and S4C). Moreover, flavopiridol
blocks PD407824-induced enhanced binding between SMAD1
and SMAD4 proteins (Figure 6F). Furthermore, C2C12 cells
were infected with lentivirus expressing Cas9 and sgRNA target-
ing CDK9. C2C12 cells infected with lentivirus expressing
sgRNA targeting GFPwere used as a negative control. After sub-
cloning, themonoallelic and biallelic knockout of CDK9 protein in
CDK9+/ and CDK9/ cells was confirmed by western blotting,
respectively (Figure S3D). Consistent with the flavopiridol treat-
ment results, CDK9+/ and CDK9/ cells lose the ability to
respond to PD407824 treatment, which further confirms that
CDK9 activation is required for the ability of PD407824 to sensi-
tize cells to BMP (Figure 6G).
It has been shown that p21 inhibits enzymatic activity of CDK9
(Chen et al., 2011). We used western blotting experiments
to measure p21 expression levels and found that either
PD407824 alone or PD407824 + BMP4 treatment significantly
decreased p21 protein levels (p < 0.01) (Figure 6H). In addition,
CHIR124 also decreased p21 protein expression levels (Fig-
ure S4E). To determine whether p21 depletion is sufficient to in-
crease the sensitivity to BMP4 treatment, C2C12 cells were in-
fected with lentivirus expressing Cas9 and sgRNA targeting
p21 and mutant cells were subcloned. C2C12 cells infected
with lentivirus expressing sgRNA targeting GFP were used as
a negative control. Western blotting confirmed the monoallelic
and biallelic knockout of p21 protein expression in p21+/ and
p21/ cells, respectively (Figure S3F). The p21+/ and p21/
cells showed increased expression of Id2 in the presence of
BMP4, comparable to PD407824-treated cells in the presence
of 3 ng/ml BMP4 (Figure 6I). In addition, flavopiridol treatment
does not block PD407824 induced decreased expression of
p21 protein (Figure S3G), suggesting that CDK9 functions as
the downstream of p21. These data suggest that PD407824
impacts BMP activity through p21 inhibition.
Overall, the data suggest that PD407824 is sufficient to block
CHK1, leading to a significant downregulation of p21, causing
activation of CDK8/9, which in turn causes depletion of
SMAD2/3. SMAD2/3 competes with SMAD1/5/9 for limiting
SMAD4, suggesting that PD407824 effectively sensitizes with
sub-threshold BMP by relieving this limitation, freeing SMAD4
to interact productively with the BMP effector SMAD1 (Fig-
ure 7A). To further validate this proposed mechanism of action,
we created CHK1//p21/ and CHK1//CDK9/ double-
knockout C2C12 cell lines, based on the parental p21/ (Fig-
ure S4E) and CDK9/ cells (Figure S4D), respectively. The
knockout of CHK1 protein in CHK1//p21/ and CHK1//
CDK9/ cells was validated by western blotting experiments
(Figure S5A). The double-knockout cells and single-knockout
cells were cultured in the absence or presence of 1 ng/ml or
3 ng/ml BMP4. Consistent with the proposed mechanism that
p21 is downstream of CHK1, there is no distinguishable differ-
ence in the levels of Id2 transcripts comparing CHK1//
p21/, CHK1/ and p21/ cells (Figure 7B). In addition,
there is no distinguishable difference in the transcript levels
of osteoblast markers, including ALP, collagen, OPN, and OC,
comparing CHK1//p21/, CHK1/ and p21/ cells after
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Figure 6. PD407824 Increases BMP Sensitivity by Depleting p21 and Activating CDK9, which Then Phosphorylates the SMAD2/3 Linker
Region, Leading to Decreased Levels of SMAD2/3 Protein and Enhanced Levels of Nuclear SMAD1
(A) PD407824 treatment increases the binding of SMAD1 and SMAD4 proteins indicated by co-immunoprecipitation.
(B) PD407824 causes depletion of SMAD2/3 protein levels, measured by western blotting; SMAD2/3 protein levels are normalized to beta-ACTIN protein levels.
(C) PD407824 induces the phosphorylation of the SMAD2/3 linker region (T179 for SMAD3). The phosphorylation level was normalized to total levels of SMAD2
protein.
(D–F) Flavopiridol, a CDK inhibitor, blocks the PD407824 induced increased Id2 transcript expression (D), upregulated T179 phosphorylation of SMAD3 and
decreased SMAD2/3 total protein (E), and increased binding of SMAD1 and SMAD4 proteins indicated by co-immunoprecipitation (F).
(G) Knockout of CDK9 blocks the synergistic effect of PD407824.
(H) PD407824 depletes p21 protein levels, shown by western blotting. The p21 protein levels are normalized to b-actin protein levels.
(I) Relative Id2 transcript expression in p21+/ and p21/ cells. Uninfected cells (wild-type [wt]) and cells infected with sgRNA targeting GFP were used as
negative controls.
See also Figure S4.7 days of osteogenic differentiation (Figure S5C). Moreover,
CDK9 knockout in CHK1/ cells ablates the ability of CHK1/
cells to respond to BMP4 treatment regarding Id2 transcript up-
regulation (Figure 7C) and capacity to differentiate toward oste-oblasts (Figure S5D). Furthermore, SB431542, a TGF-b type 1 re-
ceptor kinase inhibitor mimics the ability of PD407824 to
sensitize C2C12 cells to BMP4 treatment (Figure S5B). Finally,
the proposed mechanism was confirmed using hESCs. AfterCell Reports 15, 2063–2075, May 31, 2016 2071
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Figure 7. Suggested Mechanism of Action
(A) Suggested mechanism of action.
(B) Relative Id2 transcript expression in CHK1/, p21/, and CHK1/p21/ cells treated with or without BMP4.
(C) Relative Id2 transcript expression in CHK1/ and CHK1/CDK9/ cells treated with or without BMP4.
(D) Western blotting analysis of hESCs treated with DMSO, 10 mM PD407824, 3 ng/ml BMP4, 10 mM PD407824 + 3 ng/ml BMP4, 9 ng/ml BMP4, or 10 mM
PD407824 + 9 ng/ml BMP4. H1 cells were starved in serum-free E6 medium for 24 hr, treated with different conditions for 24 hr, and then analyzed using western
blotting.
See also Figure S5.24-hr treatment with DMSO, 10 mM PD407824, 3 ng/ml BMP4,
3 ng/ml BMP4 + 10 mM PD407824, 9 ng/ml BMP4, or 9 ng/ml
BMP4 + 10 mM PD407824, hESC lysates were analyzed with
western blotting experiments. PD407824, 3 ng/ml BMP4 +
10 mM PD407824, 9 ng/ml BMP4, and 9 ng/ml BMP4 + 10 mM
PD407824 treatment decreases p21 protein expression levels,
increases the relative phosphorylation of SMAD3 (T179), de-
creases the total levels of SMAD2/3 proteins, increases the rela-
tive phosphorylation of SMAD1/5/9 (Figures 7D and S5E), and
leads to enhanced Id2 transcript expression (Figure 3A).
DISCUSSION
We discovered a previously unreported mechanism by which in-
hibiting CHK1 can indirectly sensitize the activity of BMP. It does
so by downregulating p21 levels, which activates CHK8/9, lead-
ing to phosphorylation of the SMAD2/3 linker region and, finally,
decreased levels of SMAD2/3 proteins (Figure 6). When BMP
ligand is present, SMAD1/5/9 may therefore associate with the
increased available SMAD4, and more effectively activate BMP
downstream targets, such as Id1 and Id2. This study suggests
that SMAD4 is a limiting factor for BMP activation, consistent
with our previous observations of competition among SMADs
(Cook et al., 2011). Thus, through a screen for BMP agonists,
we found a previously unrecognized indirect mechanism to regu-
late BMP signaling by targeted depletion of SMAD2/3. While
PD407824 causes increased levels of phospho-SMAD1/5/9,
this may occur through an indirect effect by increasing steady-
state levels of active complexes, rather than, for example,
enhanced ALK2/3/6 activity. Interestingly, PD407824 itself
slightly decreased phospho-SMAD1/5/9 levels (Figure 1E),
although it does not reach significance. Previous studies have
shown that CHK1 directly induces Smurf1 phosphorylation and2072 Cell Reports 15, 2063–2075, May 31, 2016mediates Smurf1 degradation (Wang et al., 2014), which could
impact Smad1/5 proteasomal degradation (Zhu et al., 1999). It
is possible that CHK1 inhibition reduces both SMAD1/5/9 and
SMAD2/3, but much more specifically SMAD2/3. This dynamic
competition results in increased binding between SMAD1 and
SMAD4 (Figure 6A) at the expense of SMAD2/3 (Figure 6B) and
sensitizes the cells to BMP4 treatment (Figures 1D and 1G).
While BMP pathway activation leads to phosphorylation of
SMAD1/5/9, all the other TGF-b superfamily members, including
TGF-b, Activin, and Nodal, cause phosphorylation of SMAD2/3.
Many TGF-b inhibitors have been identified, most of which target
type I receptors, such as ALK4 or ALK5. Here, we identified
a class of compounds, checkpoint kinase inhibitors, which
block TGF-b signaling by causing SMAD2/3 depletion. These
compounds can therefore be used as useful tools to regulate
TGF-b signaling.
Checkpoint kinase inhibitors, including MK-8776, LY-
2606368, and LY2603618, have been used in phase 1 and 2 clin-
ical trials for the treatment of acute myeloid leukemia or breast
or ovarian cancers, by themselves or in combination therapies
(Lapenna and Giordano, 2009). Here, we found a previously un-
reported function for checkpoint kinase inhibitors, which sensi-
tize C2C12 cells hESCs with sub-threshold BMP to activate
BMP signaling. In addition, recombinant BMPs are widely used
for ESC maintenance and for directed differentiation, such as
inducing mesoderm, cardiomyocytes, hepatocytes, tropho-
blasts, germ cells, and brown adipocytes. Recent studies sug-
gested that BMP4 and BMP7 induce the white adipocyte to
brown adipocyte transition (Elsen et al., 2013). However, recom-
binant BMPs are relatively unstable and costly, which limits their
application. In our studies, we showed that small-molecule
CHK1 inhibitors synergize with BMP4 to induce hESC differenti-
ation toward a beating cardiomyocyte or cytotrophoblast stem
cell fate. Considering the broad application of BMPs in stem cell
biology, CHK1 inhibitors can be a useful reagent to control stem
cell or progenitor fate. Due to cellular context, the concentrations
of CHK1 inhibitors may need be optimized, depending on the
particular differentiation protocol and medium employed. While
recombinant BMPs have been promising in preclinical studies
and even progressed to clinical trials, the clinical outcomes
have been less dramatic than might have been hoped. These
CHK1 inhibitors, which have themselves been used in phase
1 and 2 clinical trials, might be applicable for therapeutic value,
being both stable and cost-efficient, to partially or fully replace
recombinant BMPs to treat relevant disorders, such as long-
bone non-unions, acute fractures, and spinal fusions.
EXPERIMENTAL PROCEDURES
Cell Culture
C2C12 myoblasts were purchased from the American Type Culture Collection
(ATCC). C2C12myoblasts were maintained in complete DMEM supplemented
with 10% fetal calf serum, 100 U penicillin, and 100 mg streptomycin at 37C in
5% CO2. Human ESC H1 and H9 cells were purchased from WiCell Research
Institute. Human BMP4was purchased fromR&DSystems. Tissue culture me-
dia and sera were purchased from VWR. Bright-Glo luciferase assay reagent
was purchased from Promega.
Chemicals
PD407824 and flavopiridol were purchased from Sigma-Aldrich. Purity of the
compounds was higher than 98% high-performance liquid chromatography
(HPLC) based on the manufacturer’s information. CHIR124 was purchased
from Tocris Bioscience. Unless indicated, all other chemicals were purchased
from Sigma-Aldrich.
High-Content Small-Molecule Screening Using the Id2 Reporter
C2C12 myoblasts were seeded onto 10-cm2 plates in DMEMmedium supple-
mented with 10% FBS. On the second day, the reporter plasmid pId2-LucGFP
was transfected into C2C12myoblasts according to the manufacturer’s proto-
col for X-treme GENE HP DNA Transfection Reagent (Roche) in serum-free
media. 24 hr after transfection, cells were transferred to one 384-well plate
per 10-cm dish with 5 3 105 cells/ml in DMEM supplemented with 10%
FBS. After another 24 hr, cells were cultured in serum-free conditions for an
additional 24 hr and reporter gene expression was induced upon the addition
of compounds or BMP4. Cells were then incubated for 24 hr, and luciferase ac-
tivity was measured using the Bright-Glo luciferase substrate (Promega)
following the manufacturer’s recommendations. The effect of compound on
luciferase activity was quantified by calculating the fold-induction, determined
using the ratio A/B, where A represents the activity in the presence of com-
pound or BMP4 and B represents the activity in wells with only DMSO added.
The compounds with more than 5-fold induction were chosen as the primary
hit compounds for further analysis.
Human ESC Culture and Differentiation
Human ESC lines H1 and H9were cultured on irradiated MEFs andmaintained
in hESC medium, which contains 80% DMEM/F12, 20% knockout serum
replacement, 10 ng/ml human recombinant basic fibroblast growth factor,
2 mMGlutaMax, 0.1 mM nonessential amino acids, and 0.1mM b-mercaptoe-
thanol. The medium was changed daily. For cardiac differentiation, H9 cells
were detached using 0.25%Trysin-EDTA for 1 min at room temperature to
form EBs. The EBs were cultured in suspension with hESC medium for 24 hr
and then moved to differentiation medium containing 80% knockout DMEM,
20% FBS (Hyclone), 2 mM GlutaMax, 0.1 mM nonessential amino acids,
and 0.1 mM b-mercaptoethanol with DMSO or PD407824 combined with 3
or 10 ng/ml BMP4 on ultralow cluster plates (Costar) for 4 days. On day 4,
EBs were plated on 0.1% gelatin-coated plates. The following day, differenti-
ated cells were treated with WNT antagonist I (IWR-1, Stemgent) for 3 days.Beating colonies were counted at day 10. Cells were then dissociated with Ac-
cutase for 20 min and replated on gelatin-coated plates at a 1:1 ratio. After day
10, the concentration of FBS was reduced from 20% to 2.5%. RNA was iso-
lated for qRT- PCR analysis or cells were fixed with 4% paraformaldehyde
(PFA) for 10min, followed by staining with anti-TNNT2 antibody for image anal-
ysis on day 12.
To differentiate hESCs to cytotrophoblast stem cells, hESC H1 cells were
treated with DMSO or 2.5 mM PD407824 combined with different concentra-
tions of recombinant BMP4 protein (0, 4, 6, 9, 12, or 30 ng/ml) in MEF-CM
for 7 days. RNA was isolated for qRT-PCR analysis or cells were fixed with
4% PFA for 10 min, followed by staining with anti-KRT7 antibody for image
analysis.
Western Blotting Analysis
At the indicated time points, cells were collected in complete lysis buffer
(20 mM Tris [pH 7.5], 150 mM NaCl, 50 mM NaF, 1% NP-40 substitute, and
Thermo Scientific HALT protease inhibitor cocktail 1:100) and lysates loaded
on 10% NuPage Bis-Tris pre-cast gels (Invitrogen). After being resolved by
electrophoresis, proteins were transferred to polyvinylidene fluoride (PVDF)
membranes (Bio-Rad). Membranes were blocked with 5% BSA in TBS +
0.05% Tween, and then incubated with primary antibody overnight. The anti-
bodies were rabbit anti-phospho-SMAD1/5/9 (Cell Signaling Technology,
9511), rabbit anti-SMAD1 XP (Cell Signal, 6944), rabbit anti-SMAD2/3 (Cell
Signal, 3102), rabbit anti-p21 (C-19 antibody; Santa Cruz Biotechnology, sc-
379), rabbit anti-phospho-SMAD3 T179 (Rockland, 600-401-C48S), and
mouse anti-b-actin (Sigma-Aldrich, A1978). The membranes were washed
and incubated with secondary antibody for 1 hr at room temperature in 5%
milk-TBS-0.05% Tween and developed using SuperSignal West Pico ECL
substrate (Thermo Fisher Scientific).
Construction of Lentiviral CRISPR Gene Expression Knockdown
Plasmids
sgRNA sequences were designed using the website http://www.genome-
engineering.org/. The target sequences were as follows: sgRNA-eGFP, 50-
GGGCGAGGAGCTGTTCACCG-30; sgRNA-CHK1, 50-TAGTGAAATTCTATGG
CCAC-30; sgRNA-p21, 50-CTTCGTCACGGAGACGCCGC-30; and sgRNA-
CDK9, 50-ATTGAGATTTGTCGGACCAA-30. Each target sequence was cloned
into the lentiCRISPRv2 vector (Addgene, plasmid # 52961; Sanjana et al.,
2014; Shalem et al., 2014) to make knockdown plasmids.
C2C12 cells were infected with lentivirus expressing sgRNAs. Two days af-
ter infection, cells were treated with 2 mg/ml puromycin for 48 hr. The cells after
selection were treated with compounds and used for qRT-PCR analysis.
Intracellular Fluorescence-Activated Cell Sorting Analysis
The hESC-derived cells were dissociated by Accutase (STEMCELL Technol-
ogies), fixed and stained with primary antibody at 4C overnight. Primary an-
tibodies were anti-TNNT2 (1:500) and anti-KRT7 (1:500). After washing three
times, cells were incubated with secondary antibodies for 1 hr at room tem-
perature. These were Alexa-488-conjugated donkey anti-mouse or Alexa-
Fluor-647-conjugated donkey anti-guinea pig secondary antibody (1:500)
using cytofix/cytoperm (BD Bioscience) and wash buffer (BD Biosciences)
according to instructions by the manufacturer. Flow cytometry data were
obtained using an Accuri C6 flow cytometry instrument and analyzed with
FlowJo.
Statistical Analysis
Data represent n = 3 independent biological replicates if not specifically indi-
cated. n.s. indicates a non-significant difference. p values were calculated
by unpaired two-tailed Student’s t test if not specifically indicated (*p < 0.05,
**p < 0.01, ***p < 0.001, and ****p < 0.0001).
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